Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.

Autor: Bill M; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.; Mildred Scheel Early Career Center, Medical Clinic and Policlinic I, University Hospital of the Technische Universität Dresden, Dresden, Germany.; National Center for Tumor Diseases Dresden, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Jentzsch M; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Bischof L; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Kohlschmidt J; Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Grimm J; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Schmalbrock LK; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Backhaus D; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Brauer D; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Goldmann K; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Franke GN; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Vucinic V; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Niederwieser D; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Mims AS; Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Platzbecker U; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany., Eisfeld AK; Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Schwind S; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.

Publikováno v: Blood advances [Blood Adv] 2023 Feb 14; Vol. 7 (3), pp. 436-444.

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.

Autor: Schmalbrock LK; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Germany., Dolnik A; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Cocciardi S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Sträng E; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Theis F; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Jahn N; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Panina E; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Blätte TJ; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Herzig J; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Skambraks S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Rücker FG; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Gaidzik VI; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Paschka P; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Fiedler W; Section of Pneumology, Department of Oncology, Hematology and Bone Marrow Transplantation, Hubertus Wald University Cancer Center, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Salih HR; Department of Hematology and Oncology, Eberhard Karls University Tübingen, Tübingen, Germany., Wulf G; Department of Hematology and Oncology, Georg-August-University Göttingen, Göttingen, Germany., Schroeder T; Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany., Lübbert M; Department of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Faculty of Medicine, Freiburg, Germany., Schlenk RF; National Center of Tumor Diseases, NCT-Trial Center, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Thol F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Larson RA; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Ganser A; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Stunnenberg HG; Department of Molecular Biology, Faculty of Science, Radboud University, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands., Minucci S; Department of Experimental Oncology, European Institute of Oncology, Milan, Italy., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and., Bloomfield CD; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Bullinger L; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Germany.; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Publikováno v: Blood [Blood] 2021 Jun 03; Vol. 137 (22), pp. 3093-3104.

Authentication of Primary Murine Cell Lines by a Microfluidics-Based Lab-On-Chip System.

Autor: Hong Y; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.; TUM School of Medicine, Technical University Munich, 81675 Munich, Germany., Singh N; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.; TUM School of Medicine, Technical University Munich, 81675 Munich, Germany., Bamopoulos S; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany., Gjerga E; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany., Schmalbrock LK; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany., Balabanian K; Institut de Recherche Saint Louis, Université de Paris, EMiLy, Inserm U1160, F-75010 Paris, France., Schick M; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany., Keller U; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.; German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, 13092 Berlin, Germany., Wirth M; Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.

Publikováno v: Biomedicines [Biomedicines] 2020 Dec 09; Vol. 8 (12). Date of Electronic Publication: 2020 Dec 09.

Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation.

Autor: Schmalbrock LK; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Bonifacio L; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Bill M; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Jentzsch M; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Schubert K; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Grimm J; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Cross M; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Lange T; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Vucinic V; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Pönisch W; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Behre G; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Franke GN; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Niederwieser D; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany., Schwind S; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany. Sebastian.Schwind@medizin.uni-leipzig.de.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2018 May; Vol. 53 (5), pp. 640-643. Date of Electronic Publication: 2018 Jan 15.